Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock

Key Points

• Royalty Pharma EVP Marshall Urist sold 13,684 shares on May 20 at an average price of $52.75, generating about $721,831. The sale cut his direct stake by 42.92% and was made under a pre-arranged Rule 10b5-1 trading plan.
• RPRX shares were up 0.9% to $53.55, near their 12-month high of $53.59. The stock has a market cap of $30.84 billion and is trading above both its 50-day and 200-day moving averages.
• Royalty Pharma beat EPS expectations in its latest quarterly report, posting $1.30 per share versus the $1.22 consensus, though revenue came in below forecasts. The company also announced a quarterly dividend of $0.235 per share, or $0.94 annually.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 13,684 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total transaction of $721,831.00. Following the sale, the executive vice president directly owned 18,197 shares of the company's stock, valued at $959,891.75. The trade was a 42.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Trading Up 0.9%

Shares of RPRX traded up $0.49 during trading hours on Thursday, reaching $53.55. 2,842,883 shares of the company traded hands, compared to its average volume of 3,648,985. The company's fifty day moving average price is $48.87 and its two-hundred day moving average price is $43.84. The company has a market capitalization of $30.84 billion, a price-to-earnings ratio of 36.43, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 12 month low of $32.15 and a 12 month high of $53.59.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.08. The company had revenue of $631.00 million during the quarter, compared to analysts' expectations of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Equities research analysts predict that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. Royalty Pharma's payout ratio is currently 63.95%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Citigroup upped their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. TD Cowen reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, February 27th. Finally, UBS Group upped their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $53.71.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. LM Advisors LLC purchased a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $26,000. Lloyd Advisory Services LLC. purchased a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its position in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares during the last quarter. Private Trust Co. NA raised its position in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.